Effect of acute Methylphenidate (Ritalin®) dose on visual attention, subjective mood assessments and driving performance
Our research centre has merged
The Centre for Mental Health and Brain Sciences was established in 2023 – merging together the Centre for Mental Health, the Centre for Human Psychopharmacology and the Swinburne Neuroimaging Facility – to lead Swinburne's psychological and neurobiological mental health research.
About this study
This project will examine how an acute single dose of Methylphenidate (Ritalin® 10mg) affects visual attention, subjective mood assessments and driving performance. Participants can be aged between 21 and 40 years old, in good health and have a current (valid) full driver's licence (no ‘P’ plates).
What’s involved?
Participants will be asked to attend Swinburne University on three separate occasions:
- one screening session for a maximum of 1.5 hours
- two testing sessions (one week apart) for three hours each.
In each testing session, participants will receive either Methylphenidate (Ritalin® 10mg) or a placebo only. They will be reimbursed for their time and travel for their participation in the study.
For further enquiries
Our research ethics and integrity
Our researchers are committed to the highest ethical, professional and scholarly standards. All our studies conform to the Australian Code for the Responsible Conduct of Research, Good Clinical Practice and the National Statement on Ethical Conduct in Human Research.
Explore more from our centre
Contact the Centre for Mental Health and Brain Sciences
We work with academia, industry and government to form meaningful and impactful partnerships. For more information, please email cmhbs@swinburne.edu.au.